A preclinical study reported that PD-L1-targeted lutetium-177 therapy reduced tumor volume and extended survival in a mouse model of triple-negative breast cancer. Researchers tested [177Lu]Lu-atezolizumab in athymic mice bearing MDA-MB-231 tumors and saw dose-dependent tumor shrinkage and improved median survival versus saline controls.